DUBLIN--(BUSINESS WIRE)--
Research and Markets has announced the addition of the "End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline Review, H2 2016" report to their offering.
End-Stage Kidney Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Preclinical stages are 1, 1, 4 and 2 respectively. End-Stage Kidney Disease.
End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/kq8kwt/endstage_kidney

View source version on businesswire.com: http://www.businesswire.com/news/home/20161209005462/en/